First Horizon Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

First Horizon Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$105K	Buy	4,295 +191	+5%	+$4.18K	﹤0.01%	703
2025 Q1	$85.2K	Hold	4,104	–	–	﹤0.01%	725
2024 Q4	$96.6K	Hold	4,104	–	–	﹤0.01%	710
2024 Q3	$105K	Sell	4,104 -546	-12%	-$13.9K	﹤0.01%	707
2024 Q2	$109K	Buy	4,650 +398	+9%	+$10K	﹤0.01%	667
2024 Q1	$122K	Buy	4,252 +179	+4%	+$5.38K	﹤0.01%	637
2023 Q4	$134K	Buy	4,073 +1,043	+34%	+$28.4K	﹤0.01%	583
2023 Q3	$84.4K	Buy	3,030 +36	+1%	+$1.18K	﹤0.01%	676
2023 Q2	$102K	Buy	2,994 +74	+3%	+$2.33K	﹤0.01%	637
2023 Q1	$87.8K	Buy	2,920 +69	+2%	+$2.14K	﹤0.01%	683
2022 Q4	$80.5K	Buy	2,851 +126	+5%	+$4K	﹤0.01%	690
2022 Q3	$89K	Buy	2,725 +55	+2%	+$2.02K	﹤0.01%	643
2022 Q2	$84K	Buy	+2,670	New	+$93.4K	﹤0.01%	743
2022 Q1	–	Sell	-414	Closed	-$25K	–	1734
2021 Q4	$25K	Sell	414 -307	-43%	-$21.2K	﹤0.01%	1188
2021 Q3	$53K	Sell	721 -139	-16%	-$11.7K	﹤0.01%	870
2021 Q2	$79K	Buy	860 +121	+16%	+$10.3K	﹤0.01%	621
2021 Q1	$65K	Buy	+739	New	+$73.3K	﹤0.01%	637

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

First Horizon Advisors's ARKG Position: Q2 2025 in Review

First Horizon Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 4.7% in Q2 2025, buying an estimated $4.18K and bringing the position to 4,295 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #703.

First Horizon Advisors first reported a position in ARKG in Q1 2021 and has held it in 17 quarters since. The position peaked at $134K in Q4 2023. 214 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

First Horizon Advisors held 4,295 shares of ARK Genomic Revolution ETF worth $105K as of Q2 2025.
First Horizon Advisors bought 191 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $4.18K.
ARK Genomic Revolution ETF made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #703 holding.
First Horizon Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and has held it in 17 quarters since.
First Horizon Advisors's ARK Genomic Revolution ETF position peaked at $134K in Q4 2023.
214 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.